

WHO Clinical operations for COVID-19: Therapeutics and oxygen

Member state briefing, 5 August 2021

Last briefing 17 June 2021

Janet V Diaz, MD


Lead, Clinical management COVID-19 response

WHO, Health Emergencies Programme

Comprehensive, multi-disciplinary, holistic: from triage through recovery




Staff: multi-disciplinary, trained, safe, outpatient, inpatient




Structures: patient flow, ventilation, IPC controls



Supplies: medicines, biomedical equipment



Systems: home care, community care, referral paths



Study: clinical characterization, clinical trials,



Standards: guidelines, tools,

Therapeutics and COVID-19


<https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1>

New strong recommendation for use of IL6-receptor blockers for patients with severe/critical COVID-19 (tocilizumab, sarilumab)

- Immunomodulator function
- Reduction in mortality and need for mechanical ventilation
- Benefit additive to oxygen + steroids.


Access Update: IL6 Receptor Blockers

- High Interest in LMIC to procure and integrate new treatment recommendation into national protocols
- Estimate 50 countries without regulatory approval for known indication of rheumatoid arthritis
- Market remains constrained in availability and price of product
- Negotiations on price, availability and regulatory processes underway with pharmaceutical companies with the aim to develop demand-based forecast and supply chain



In pipeline:
REGN-COV2
(**casirivimab/imdevimab**), to
publish within 3-4 weeks
--anticoagulants, con plasma,

Research and innovation: O2CoV2 respiratory observational research study




- **Full title:** *Oxygen requirements and approaches to respiratory support in patients with COVID-19 in low- and middle-income countries*
- **179 Expressions of Interest (EOI)** received from **51 countries** from all WHO regions; minimum target of 5 countries per region met
- Steering committee meet 28 July 2021 and **site selection completed**. Total of **5 countries per region selected**, and at **least 2 sites per country**.
- On-boarding to begin in September 2021.


Research and innovation: COVID-19 Clinical data platform

Clinical features and prognostic factors for COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV2 infection

- In this hospitalized population, PLHIV were at increased risk of severe or critical disease at hospital admission (aOR 1.06, 95% CI 1.02–1.11) compared to HIV-negative individuals, after adjusting for age, sex and the presence of underlying conditions (diabetes, tuberculosis, malignant neoplasms and chronic cardiac and pulmonary diseases).



In pipeline: dashboard on website




Capacity building for health work force : biomedical and clinical

<u>Step 1</u> Selecting the right medical equipment	<u>Step 2</u> Getting the equipment ready (set up, installing and testing)	<u>Step 3</u> Clinically using the equipment (patient care)	<u>Step 4a</u> Decontamination of consumables and equipment (cleaning, disinfection and sterilization)	<u>Step 4a</u> Decontamination of consumables and equipment (cleaning, disinfection and sterilization)	<u>Step 5</u> Corrective maintenance of the equipment	<u>Step 6</u> Preventative maintenance of the equipment	<u>Step 7</u> Decommissioning of the equipment
In progress	1. Pulse oximeter 2. Patient monitor 3. Oxygen cylinder 4. High Flow Nasal Cannula 5. CPAP and BiPAP 6. Mechanical ventilator	In progress	In progress	In progress	In progress	In progress	In progress

First 6 training videos posted on  YouTube


OpenWHO.org **course development underway**
#LearningSavesLives



Country support for COVID-19: oxygen technical and operations



WHO Oxygen Country Support




Data Source: World Health Organization,
Map Production: WHO Health Emergencies Programme
Request ID: COVID19_40

0 3,000 6,000 km
© World Health Organization 2021. All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. [1] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).




Country Support: Increasing local capacity and technical support



Partnerships and coordination: oxygen technical cooperation, biomedical consortium, ACT-A emergency oxygen task force

GF eligible Countries with financial allocations 2020-2022 with at least one identified TA partner



Countries with 2+ partners	Partners
Burkina Faso	WHO, UNICEF, PATH
Cameroon	WHO, CHAI
Democratic Republic of the Congo	WHO, PATH, CHAI
Ethiopia	CHAI, Assist International
Ghana	WHO, CHAI
India	WHO, UNICEF, PATH, CHAI
Kenya	PATH, CHAI
Lesotho	WHO, PIH
Liberia	CHAI, PIH
Madagascar	WHO, UNICEF
Malawi	WHO, UNICEF, PATH, PIH
Mozambique	WHO, CHAI
Nigeria	WHO, UNICEF, CHAI
Paraguay	WHO, UNICEF
Peru	WHO, PIH
Rwanda	CHAI, PIH
Senegal	UNICEF, PATH
Sierra Leone	WHO, UNICEF, PIH
Somalia	WHO, UNICEF
United Republic of Tanzania	UNICEF, PATH, CHAI
Uganda	WHO, CHAI, Assist International
Zambia	WHO, UNICEF, PATH, CHAI

GF eligibility status

- Dark blue square: GF eligible country with financial allocation 2020-2022
- Light blue square: GF non-eligible country


Technical Assistance Partners

- Dark blue circle: WHO
- Orange circle: UNICEF
- Yellow circle: PATH
- Green circle: CHAI
- Red circle: PIH
- Grey circle: 2+ partners
- Light green circle: Assist International



Data Source: World Health Organization,
Map Production: WHO Health Emergencies Programme
Request ID: COVID19_40

Not applicable



© World Health Organization 2021. All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. [1] All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).